| Literature DB >> 32939338 |
Randall C Mazzarino1,2,3,4, Veronika Baresova5, Marie Zikánová5, Nathan Duval1,2,3, Terry G Wilkinson1,2, David Patterson1,2,4, Guido N Vacano1,2.
Abstract
In de novo purine biosynthesis (DNPS), 5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase (EC 2.1.2.3)/inosine monophosphate cyclohydrolase (EC 3.5.4.10) (ATIC) catalyzes the last two reactions of the pathway: conversion of 5-aminoimidazole-4-carboxamide ribonucleotide [aka Z-nucleotide monophosphate (ZMP)] to 5-formamido-4-imidazolecarboxamide ribonucleotide (FAICAR) then to inosine monophosphate (IMP). Mutations in ATIC cause an untreatable and devastating inborn error of metabolism in humans. ZMP is an adenosine monophosphate (AMP) mimetic and a known activator of AMP-activated protein kinase (AMPK). Recently, a HeLa cell line null mutant for ATIC was constructed via CRISPR-Cas9 mutagenesis. This mutant, crATIC, accumulates ZMP during purine starvation. Given that the mutant can accumulate ZMP in the absence of treatment with exogenous compounds, crATIC is likely an important cellular model of DNPS inactivation and ZMP accumulation. In the current study, we characterize the crATIC transcriptome versus the HeLa transcriptome in purine-supplemented and purine-depleted growth conditions. We report and discuss transcriptome changes with particular relevance to Alzheimer's disease and in genes relevant to lipid and fatty acid synthesis, neurodevelopment, embryogenesis, cell cycle maintenance and progression, extracellular matrix, immune function, TGFβ and other cellular processes.Entities:
Keywords: 5-aminoimidazole-4-carboxamide ribonucleoside, (AICAr); 5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase/inosine monophosphate cyclohydrolase, (ATIC); 5-aminoimidazole-4-carboxamide ribonucleotide, (ZMP); 5-formamido-4-imidazolecarboxamide ribonucleotide, (FAICAR); AICA-ribosiduria; AMP-activated protein kinase, (AMPK); Alzheimer's disease; Development; Purine synthesis; RNA-seq; Tuberous Sclerosis Complex 1 and 2, (TSC1 and TSC2); adenine phosphoribosyltransferase, (APRT); adenosine monophosphate, (AMP); adenosine triphosphate, (ATP); adenylosuccinate lyase, (ADSL); arachidonic acid, (AA); cyclooxygenase, (COX); cytochrome, P450 (CYP); cytosolic phospholipase A2, (cPLA2); de novo purine synthesis, (DNPS); differentially expressed gene, (DEG); false discovery rate, (FDR); fatty acid amide hydrolase, (FAAH); fetal calf macroserum, (FCM); fetal calf serum, (FCS); fragments per kilobase of exon per million reads mapped, (FPKM); gene ontology, (GO); guanosine monophosphate, (GMP); inosine monophosphate, (IMP); interferon, (INF); lipoxygenase, (LOX); mammalian Target of Rapamycin, (mTOR); minus adenine crATIC to minus adenine WT comparison, (MM); phospholipase, (PLA); phosphoribosyl pyrophosphate, (PRPP); phosphoribosylaminoimidazole carboxylase/phosphoribosylaminoimidazole succinocarboxamide synthetase, (PAICS); plus adenine crATIC to plus adenine WT comparison, (PP); xanthine monophosphate, (XMP)
Year: 2020 PMID: 32939338 PMCID: PMC7479443 DOI: 10.1016/j.ymgmr.2020.100642
Source DB: PubMed Journal: Mol Genet Metab Rep ISSN: 2214-4269
Fig. 1De novo purine synthesis pathway. DNPS is accomplished via the conversion of PRPP to IMP which is subsequently converted to AMP or GMP. The HeLa ATIC KO, crATIC, is indicated.
Fig. 2crATIC requires adenine for proliferative growth. HeLa (A,B) and crATIC (C,D) cells were plated and cultured in adenine-supplemented (A,C) or adenine-depleted (B,D) media. Plates were stained with crystal violet. (For interpretation of the references to color in this figure legend, the reader is referred to the web version of this article.)
Fig. 3ZMP accumulates in crATIC. crATIC was grown in media with or without supplemental adenine. Accumulation of ZMP was measured by HPLC-EC and was observed only in cells grown in adenine-depleted media.
Fig. 4log(2) fold change of DEGs in cell lines under experimental conditions. A and B: DEGs in PP (A) and MM (B) conditions. C and D: 100 most positively and 100 most negatively changed DEGs in PP (C) and MM (D) conditions.
Number of unique and shared DEGs.
| Total DEGs | Top 200 DEGs | |
|---|---|---|
| Shared | 1083 | 156 |
| Unique PP | 228 | 44 |
| Unique MM | 579 | 44 |
Fig. 5Principle component analysis of crATIC and HeLa experimental groups. PCA shows robust differences by cell type.
Fig. 6Notable GO groups from ClueGO analysis.
Fig. 7Candidate gene verification by qPCR. Gene transcription in PP and MM conditions measured by A) log(2)fold change of FPKM values from RNA-seq and B) Ct values from qPCR. Values were normalized to β-Actin.